Details for Patent: 7,659,285
✉ Email this page to a colleague
Which drugs does patent 7,659,285 protect, and when does it expire?
Patent 7,659,285 protects NUPLAZID and is included in two NDAs.
This patent has thirty-five patent family members in twenty-one countries.
Summary for Patent: 7,659,285
| Title: | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| Abstract: | Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. |
| Inventor(s): | Weiner; David M. (San Diego, CA), Davis; Robert E. (San Diego, CA), Brann; Mark R. (Rye, NH), Andersson; Carl-Magnus A. (Hjarup, SE), Uldam; Allan K. (Ballerup, DK) |
| Assignee: | Acadia Pharmaceuticals, Inc. (San Diego, CA) |
| Application Number: | 11/416,855 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,659,285 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 7,659,285
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | CAPSULE;ORAL | 210793-001 | Jun 28, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS | ⤷ Sign Up | ||||
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-002 | Jun 28, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS | ⤷ Sign Up | ||||
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,659,285
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 407117 | ⤷ Sign Up | |||
| Austria | 512136 | ⤷ Sign Up | |||
| Australia | 2004206886 | ⤷ Sign Up | |||
| Brazil | PI0406591 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
